PAXIL CR

Compare PAXIL CR  to:
Compare
Compare

Generic Name for PAXIL CR

Paroxetine (as HCl) 12.5mg, 25mg, 37.5mg; controlled-release e-c tabs.

Legal Classification:

Rx

Pharmacological Class for PAXIL CR

SSRI.

Manufacturer of PAXIL CR

GlaxoSmithKline Pharmaceuticals

Indications for PAXIL CR

Depression. Premenstrual dysphoric disorder (PMDD).

Adult dose for PAXIL CR

Swallow whole. Give once daily, usually in the AM, adjust by 12.5mg/day at 1-week intervals. Depression: initially 25mg/day; max 62.5mg/day. PMDD: Give daily throughout menstrual cycle or intermittently (start 14 days before expected menses onset through 1st full day of menses): initially 12.5mg/day; usual max 25mg/day. Elderly, debilitated, severe hepatic or renal impairment: initially 12.5mg/day; max 50mg/day.

Children's dosing for PAXIL CR

Not recommended.

Also:

Contraindications for PAXIL CR

Concomitant pimozide, thioridazine (may cause QTc prolongation). During or within 14 days of MAOIs (including linezolid).

Precautions for PAXIL CR

History of seizures (discontinue if occurs), mania/hypomania. Monitor for serotonin syndrome or neuroleptic malignant syndrome-like signs and symptoms; discontinue if occurs. Conditions that affect metabolism or hemodynamic response. Cardiac disease. ECT. Narrow angle glaucoma. Suicidal tendencies (monitor). Write ℞ for smallest practical amount. Avoid abrupt cessation; reduce dose gradually. Reevaluate periodically. Elderly. Labor & delivery. Pregnancy (Cat.D); avoid use. Nursing mothers.

Interactions for PAXIL CR

See Contraindications. Do not start MAOI until at least 2 weeks after discontinuing paroxetine. Concomitant SSRIs, SNRIs, tryptophan: not recommended. Avoid alcohol. Potentiation with other protein bound drugs. Caution with drugs that affect coagulation (eg, warfarin, NSAIDs). Potentiated by cimetidine. Antagonized by fosamprenavir/ritonavir. May affect, or be affected by, drugs metabolized by CYP2D6, including tricyclic antidepressants, fluoxetine, phenothiazines, risperidone, atomoxetine, tamoxifen, Class 1C antiarrhythmics, quinidine. Monitor digoxin, phenytoin, phenobarbital, theophylline, warfarin. Reduce procyclidine dose if anticholinergic effects occur. Caution with triptans, linezolid, lithium, tramadol, St. John's wort or dopamine antagonists; may cause serotonin syndrome (eg, agitation, tachycardia, incoordination, hyperreflexia). Hormonal contraceptives and PMDD treatment: see literature.

Adverse Reactions for PAXIL CR

GI upset, asthenia, sweating, decreased appetite, somnolence, dizziness, insomnia, nervousness, headache, decreased libido, tremor, akathisia, dry mouth, abnormal ejaculation, genital disorders, impotence, hyponatremia, abnormal bleeding, others; serious discontinuation symptoms (monitor); rare: neuroleptic malignant syndrome.

How is PAXIL CR supplied?

CR—30
Tabs 10mg, 30mg, 40mg—30
20mg—30, 90
Susp—250mL

Related Disease:

Depression
Premenstrual dysphoric disorder

Related Resources

Oleptro approved for major depressive disorder (MDD)

February 03, 2010

The FDA has approved Oleptro (trazodone HCl extended-release tablets, from Labopharm), a once-daily formulation of trazodone, for the treatment of major depressive disorder (MDD) in adults.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Seroquel XR approved for adjunctive treatment of major depressive disorder (MDD)

December 07, 2009

Seroquel XR (quetiapine fumarate extended-release tablets, from AstraZeneca) has been approved by the FDA as adjunctive treatment to antidepressants in adults with major depressive disorder (MDD).

Zyprexa approved for schizophrenia and bipolar I disorder in adolescents

December 07, 2009

The FDA has approved Zyprexa (olanzapine, from Lilly) tablets for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents 13-17 years of age.

FDA warns of birth defects with valproate sodium, valproic acid, and divalproex sodium

December 03, 2009

The FDA has notified healthcare professionals and patients about the increased risk of neural tube defects and other major birth defects (eg, craniofacial defects and cardiovascular malformations) in babies exposed to valproate sodium and related products (valproic acid and divalproex sodium) during pregnancy.